Study Comparing Neoadjuvant Versus Adjuvant Stereotactic Radiotherapy of Brain Metastases

Starting soon · Not applicable

Conditions studied: Brain Metastases, Adult

In brief

The purpose of this study is to evaluate the local control rate on the target lesion at 6, 12, and 24 months after treatment with neoadjuvant stereotactic radiotherapy (SRS NEO group) compared to standard care, adjuvant stereotactic radiotherapy (POST OP SRS group).

Key facts

Study ID

NCT07437820

Run by

GCS Ramsay Santé pour l'Enseignement et la Recherche

People needed

68

Starts

2026-07-01

Expected to finish

2030-06-30

Last updated by the study team

2026-06-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged 18 years and older;
• Patients with 1 to 12 brain metastases on preoperative MRI, at least one of which (contrast enhancement of at least 1 cm) is accessible for the most complete possible resection (target lesion);
• Patients with a Karnofsky performance score of ≥ 70;
• Patients able to perform neurocognitive tests without assistance;
• Patients who understand the study and agree to attend all visits;
• Patients who have signed a written informed consent form;
• Affiliation with a social security system.

You may not qualify if…

• Patient who has already been treated with surgery, radiosurgery, and/or radiotherapy for the target brain metastasis;
• Medical contraindication to MRI;
• Patient with an estimated life expectancy of ≤ 3 months;
• Patients participating in another clinical trial, or who are in the exclusion period of another clinical trial;
• Patients unable to complete a self-administered questionnaire;
• Patients from a vulnerable population.

Where it is running

• Hôpital Privé Clairval — Marseille, France

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.